

Please type a plus sign (+) inside this box

JUL 27 2004

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Approved for use through 10/31/98. GPO 1997-090  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b> Application Number   10/076,191 Filing Date   02-14-2002 First Named Inventor   SMITH Group Art Unit   1614 Examiner Name   Dwayne C. Jones Attorney Docket Number   USAV2001/0002 - US - NP	
Sheet	1	of	2

## U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	9/13/01
-----------------------	---	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through station if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)  
Approved for use through 10/31/08. GMPR 0851-0031

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/076,191
				Filing Date	02-14-2002
				First Named Inventor	SMITH
				Group Art Unit	1614
				Examiner Name	Dwayne C. Jones
(use as many sheets as necessary)				Attorney Docket Number	USA2001/0002 - US - NP
Sheet	2	of	2		

#### **OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

EXAMINER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	C.T. BEVER, JR., The Current Status of Studies of Aminopyridines in Patients with Multiple Sclerosis, Annals of Neurology, Boston, MA, Vol. 36, 1994, pp. S118-S121	T2
	L. TANG et al., 4-Aminopyridine Derivatives: A Family of Novel Modulators of Voltage-Dependent Sodium Channels, Drug Development Research, Vol. 44, No. 1, May 1998, pp. 8-13	
	L. TANG et al., Effects of besipirdine at the voltage-dependent sodium channel, British Journal of Pharmacology, Vol. 116, No. 5, 1995, pp. 2468-2472	
	M ABOU-GHARBIA et al., IV Congress of the ECNP, Aggression and anxiety are the first components to respond to antidepressant therapy, Drug News and Perspectives, Vol. 4, No. 10, Dec. 1, 1991, pp. 647-650	
	P. Villoslada et al., Human Nerve Growth Factor Protects Common Marmosets against Autoimmune Encephalomyelitis by Switching the Balance of T Helper Cell Type 1 and 2 Cytokines within the Central Nervous System, Journ. of Experimental Medicine, Vol. 191, No. 10, 15 May 2000, pp. 1799-1806	
	R.M. EGLEN et al., Muscarinic receptor ligands and their therapeutic potential, Current Opinion in Chemical Biology, Vol. 3, No. 4, August 1999, pp. 426-432	
	W.J. MYSIW et al., Medications To Enhance Cognitive Functioning, Physical Medicine and Rehabilitation Clinics of North America, 1997, pp. 781-800	

Examiner Signature Johnne Jones Date Considered 9/3/04

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.